Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

EURORDIS

- PMLiVE

A rare opportunity

Sobi’s Neil Dugdale on how the UK’s approach to rare diseases is changing

Shire Basingstoke

Shire completes $32bn Baxalta merger

Creates world leading rare diseases specialist

- PMLiVE

Should We Care About Rare Diseases? By Alastair Kent

Alastair Kent, OBE, the Director of Genetic Alliance UK and chair of Rare Disease UK tells us why it’s so important to care about rare disease and why we should...

Say Communications

Pharma Market Research Report – Predictions for 2016

PMR invited US President Harriet Kozak to submit her predictions for 2016

Research Partnership

- PMLiVE

Baxalta agrees to $32bn Shire takeover

Deal will  create one of the industry's top rare disease firms

- PMLiVE

Another lost decade for research?

What does the patent landscape look like for antibiotics, vaccines and orphan drugs?

EU flag

Wakix backed for European approval in narcolepsy

Bioprojet Pharma’s orphan drug given a positive opinion by CHMP

- PMLiVE

Orphan drug firm Sobi opens new European base

Company'sBrussels office will also house its Benelux operations

- PMLiVE

FDA grants Tocagen’s glioblastoma drug orphan status

Puts the brain cancer gene therapy in-line for development incentives

- PMLiVE

Shire launches rare disease website

Hereditary angioedema sitesupports its Me, Not HAE campaign

Shire Basingstoke

Shire links with US hospital for rare disease research

Willwork with Cincinnati Children's Hospital Medical Centre novel therapies

- PMLiVE

FDA grants orphan drug status to Treeway’s ALS treatment

Amyotrophic Lateral Sclerosis drug TW001 gainsregulatory benefits

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links